HELSINKI, Finland, July 30, 2024 /PRNewswire/ — DEEP Measures announces its collaborative platform to build digital measures in clinical trials, boosting the second digital revolution of the 50 billion USD clinical research market. Twenty years ago, the industry started to collect clinical data with digital systems. Today, DEEP will facilitate the creation of precision digital measures, enabling direct capture of clinical data anywhere, any time. This offers a whole new perspective into human health and better understanding of how diseases and interventions impact people in their daily lives. Better measures improve the quality and accuracy of clinical data, speeds up clinical development, and enables faster access to better and more personalized therapeutics, medical devices and healthcare.
“With DEEP, fit-for-purpose digital measures like biosensors or wearables can be deployed into clinical trials.” says Kai Langel, CEO of DEEP Measures. “Ultimately we improve clinical development with more relevant and better performing measures and achieve regulatory success for drug approvals.”
Traditionally, patient outcomes are measured with subjective questions, doctor interviews or lab results. Including digital measures provides an additional, more continuous, human-centric and objective evidence generation.
